IP Library Granted Patent US 8,609,819
Granted Patent B2
US 8,609,819 · App. 13/486,011 · Granted Dec 17, 2013

Extracellular serine protease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,609,819
App. No.
13/486,011
Granted
Dec 17, 2013
Kind
B2
Abstract

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.

Claims (14)

1. An isolated antibody or immunologically-active fragment thereof that specifically binds to a sequence shown in SEQ ID NO: 7.

2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody, a polyclonal antibody or a chimeric antibody.

3. The antibody of claim 2 , wherein the antibody is a monoclonal antibody and the sequence is a recombinant protein.

4. An isolated antibody or immunologically-active fragment thereof that specifically binds to a sequence shown in SEQ ID NO: 75.

5. The antibody of claim 4 , wherein the antibody is a monoclonal antibody, a polyclonal antibody or a chimeric antibody.

6. The antibody of claim 5 , wherein the antibody is a monoclonal antibody and the sequence is a recombinant protein.

7. A kit comprising the antibody or immunologically-active fragment thereof of claim 4 and a detectable label linked thereto.

8. A compound, comprising:

the antibody of claim 1 ; and

a targeting moiety and a therapeutic moiety each linked to said antibody.

9. A kit comprising the antibody or immunologically-active fragment thereof of claim 4 .

10. A compound, comprising:

the antibody of claim 4 ; and

a targeting moiety and a therapeutic moiety each linked to said antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2017
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 044037/0496 →